China targets direct competition with Big Pharma by 2030

01The Story新闻事实

China’s latest pharmaceutical industry plan sets ambitious targets for innovation, company scale and global drug sales from 2026 to 2030. The strategy comes as Western drugmakers expand partnerships with Chinese biotechs, raising debate over whether licensing deals strengthen global medicine pipelines or help create a future strategic dependency on China.中国最新发布的医药产业规划为2026年至2030年的创新、企业规模和全球药品销售设定了雄心勃勃的目标。随着西方制药企业扩大与中国生物科技公司的合作，外界开始讨论，这些授权交易是在强化全球药物研发管线，还是可能造成未来对中国的战略依赖。

China’s 2026-2030 pharmaceutical plan calls for a major increase in the industry’s core competitiveness and international influence.中国2026年至2030年医药产业规划提出，要大幅提升产业核心竞争力和国际影响力。
The plan aims for China-developed first-in-class drugs to account for one-quarter of the global total.该规划提出，中国研发的全球首创新药应占全球总量的四分之一。
China expects its innovative drug sector to grow by at least 20% annually on average.中国预计创新药产业年均增速将达到至少20%。
The plan envisions 50 companies with annual revenue above roughly $1.5 billion and at least five Chinese drugs with global sales above $1 billion.该规划设想培育50家年收入超过约15亿美元的企业，并打造至少5款全球销售额超过10亿美元的中国药品。
Overseas licensing deals for Chinese drugs have already exceeded $120 billion this year, according to the Chinese government.据中国政府称，今年中国药品的海外授权交易额已经超过1200亿美元。

China’s policy targets and expanding licensing activity suggest a shift from supplying medicines and drug candidates to competing directly for global biopharmaceutical leadership.中国的政策目标和不断扩大的授权交易表明，其角色正从药品及候选药物供应方转向全球生物医药领导权的直接竞争者。

023 Dimensions维度分析

Future signal前瞻信号

Scale-up targets产业规模目标

The five-year plan combines growth targets with specific benchmarks for corporate scale and globally successful medicines. These goals indicate that China wants to build a broad commercial base rather than rely mainly on individual licensing deals.这项五年规划将增长目标与企业规模和全球畅销药物的具体指标结合起来，显示中国希望建立广泛的商业基础，而不只是依赖单笔授权交易。

Annual innovative drug sector growth target创新药产业年均增长目标

2026-20302026年至2030年20 %

by 2030到2030年50 companies

by 2030到2030年1.5 billion USD

The plan calls for first-in-class drugs developed in China to make up 25% of the global total.该规划提出，中国研发的全球首创新药应占全球总量的25%。
It also targets at least five Chinese drugs with global sales exceeding $1 billion.该规划还提出，至少要有5款中国药品的全球销售额超过10亿美元。

Contradiction矛盾之处

Licensing as a competitive channel授权交易成为竞争渠道

Partnerships give Western pharmaceutical companies access to Chinese drug candidates while potentially giving Chinese manufacturers insight into global development and commercialization. The source presents these deals as both a near-term pipeline solution and a possible contributor to China’s longer-term competitive rise.合作让西方制药企业获得中国候选药物，同时也可能让中国企业学习全球药物开发和商业化经验。报道将这些交易描述为短期管线补充，也可能成为中国长期竞争力上升的推动因素。

Overseas licensing deal value for Chinese drugs中国药品海外授权交易额

120 billion USD120十亿美元

this year今年

Large pharmaceutical companies are seeking new products as major medicines lose patent protection.随着主要畅销药物失去专利保护，大型制药企业正在寻找新的产品。
Some experts say licensing deals allow Chinese manufacturers to learn from Western pharmaceutical companies.一些专家表示，授权交易让中国企业能够向西方制药公司学习。

Future signal前瞻信号

Supply-chain and national security concerns供应链与国家安全担忧

Critics warn that moving manufacturing and research toward China could create leverage if geopolitical tensions affect medical supplies. The article notes that this risk is not currently established for medical products, but experts see it as a possible future concern.批评者警告，如果制造和研发进一步转向中国，地缘政治紧张局势可能影响医疗产品供应并形成战略杠杆。报道指出，这种风险目前尚未在医疗产品领域成为现实，但专家认为它可能成为未来隐患。

Some U.S. experts argue that dependence on Chinese drug supply could become a national security issue.一些美国专家认为，对中国药品供应的依赖可能演变为国家安全问题。
The Treasury Department is drafting rules expected to allow most pharmaceutical licensing deals with China to continue.美国财政部正在起草相关规则，预计将允许大多数对华医药授权交易继续进行。

03Timeline时间线

2026-09-18 China’s latest pharmaceutical industry plan was released, according to the linked government summary.根据所链接的中国政府摘要，中国最新的医药产业规划发布。
2026-10-01 Axios reported on China’s strategy to compete directly with large Western pharmaceutical companies.Axios报道了中国直接与西方大型制药企业竞争的战略。

Key takeaway核心结论

China is using a five-year industrial strategy and expanding international partnerships to move toward direct competition in biopharmaceutical innovation.中国正通过五年产业战略和不断扩大的国际合作，推动自身成为生物医药创新领域的直接竞争者。

04What to Watch后续关注

Whether China reaches its targets for innovative drug growth, company revenue and global first-in-class medicines by 2030.到2030年，中国能否实现创新药增长、企业收入和全球首创新药占比等目标。
Whether U.S. rules continue to permit most pharmaceutical licensing deals with China.美国相关规则是否继续允许大多数对华医药授权交易。
Whether licensing partnerships lead to stronger Chinese capabilities in global drug development and commercialization.授权合作是否会进一步提升中国在全球药物开发和商业化方面的能力。
Whether concerns about dependence on Chinese medical products affect future U.S. policy.对中国医疗产品依赖的担忧是否会影响美国未来政策。

05Uncertainties不确定因素

The article does not establish whether China will achieve the plan’s targets by 2030.报道没有确定中国能否在2030年前实现规划目标。
The potential national security leverage over medical products remains a future possibility rather than a current condition.中国对医疗产品形成国家安全杠杆目前仍是未来可能性，而不是已存在的现实。
The source does not specify how proposed U.S. rules would affect individual licensing agreements.报道没有说明拟议中的美国规则将如何影响具体授权协议。

06Sources信息来源

China eyes competition with Big Pharma over next 5 years - AxiosChina eyes competition with Big Pharma over next 5 years - Axios Axios · 2026-10-01

Share this analysis 分享此深度分析

X Facebook LinkedIn WhatsApp